Evaluating the effects of Intravenous Immunoglobulin (IVIg) on the management of severe COVID-19 cases: A randomized controlled trial

被引:58
作者
Tabarsi, Payam [1 ]
Barati, Saghar [2 ]
Jamaati, Hamidreza [3 ]
Haseli, Sara [3 ]
Marjani, Majid [4 ]
Moniri, Afshin [5 ]
Abtahian, Zahra [4 ]
Dastan, Alireza [6 ]
Yousefian, Sahar [2 ,3 ]
Eskandari, Raha [3 ]
Saffaei, Ali [7 ]
Monjazebi, Fatemeh [8 ]
Vahedi, Abdolbaset [9 ]
Dastan, Farzaneh [2 ,3 ]
机构
[1] Shahid Beheshti Univ Med Sci, Natl Res Inst TB & Lung Dis NRITLD, Clin TB & Epidemiol Res Ctr, Tehran, Iran
[2] Shahid Beheshti Univ Med Sci, Sch Pharm, Dept Clin Pharm, Rafsanjani Highway,Valiasr Ave, Tehran 615314155, Iran
[3] Shahid Beheshti Univ Med Sci, Natl Res Inst TB & Lung Dis NRITLD, Chron Resp Dis Res Ctr CRDRC, Tehran, Iran
[4] Shahid Beheshti Univ Med Sci, Masih Daneshvari Hosp, Natl Res Inst TB & Lung Dis NRITLD, Clin TB & Epidemiol Res Ctr, Tehran, Iran
[5] Shahid Beheshti Univ Med Sci, Masih Daneshvari Hosp, Natl Res Inst TB & Lung Dis NRITLD, Virol Res Ctr, Tehran, Iran
[6] Univ Calif, Ernest & Julio Gallo Management Program, Sch Engn, Merced, CA USA
[7] Shahid Beheshti Univ Med Sci, Sch Pharm, Dept Clin Pharm, Student Res Comm, Tehran, Iran
[8] Shahid Beheshti Univ Med Sci, Sch Nursing & Midwifery, Dept Med Surg Nursing, Tehran, Iran
[9] Shahid Beheshti Med Univ, Masih Daneshvari Hosp, Chron Resp Dis Res Ctr CRDRC, Tehran, Iran
关键词
IVIg; Intravenous Immunoglobulin; COVID-19; Coronavirus; Pulmonary infection; CLINICAL CHARACTERISTICS; CORONAVIRUS;
D O I
10.1016/j.intimp.2020.107205
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: The newly discovered coronavirus has turned into coronavirus disease 2019 (COVID-19) pandemic and it rages at an unprecedented rate. Considering the findings of previous studies on the use of Intravenous Immunoglobulin (IVIg) for treating severe H1N1 infection and the satisfying results for reducing viral load and mortality, this study aimed to investigate the potential usefulness of IVIg for the management of severe cases. Methods: In this randomized controlled trial, 84 patients were included: 52 in the IVIg group and 32 in the control group. The intervention group received IVIg at a dose of 400 mg/kg, IV, daily for three days. Both groups received hydroxychloroquine, lopinavir/ritonavir and supportive care. The demographic data, mortality rate, the need for mechanical ventilation, length of stay in hospital and in Intensive Care Unit (ICU), and imaging findings were recorded and compared in terms of the mentioned factors. Results: The mean time from admission to IVIg initiation was 3.84 +/- 3.35 days. There was no significant difference between the two groups in terms of mortality rate (P-value = 0.8) and the need for mechanical ventilation (P-value = 0.39). The length of hospital stay was significantly lower for the control group than that of the intervention group (P-value = 0.003). There was a significant positive relationship between the time from hospital admission to IVIg initiation and the length of stay in the hospital and ICU among the survivors (P-value < 0.001 and =0.01, respectively). Conclusions: Our findings did not support the use of IVIg in combination with hydroxychloroquine and lopinavir/ritonavir in treatment of severe COVID-19 cases.
引用
收藏
页数:5
相关论文
共 12 条
[1]   High-Dose Intravenous Immunoglobulin as a Therapeutic Option for Deteriorating Patients With Coronavirus Disease 2019 [J].
Cao, Wei ;
Liu, Xiaosheng ;
Bai, Tao ;
Fan, Hongwei ;
Hong, Ke ;
Song, Hui ;
Han, Yang ;
Lin, Ling ;
Ruan, Lianguo ;
Li, Taisheng .
OPEN FORUM INFECTIOUS DISEASES, 2020, 7 (03) :1-6
[2]   Clinical Characteristics of Coronavirus Disease 2019 in China [J].
Guan, W. ;
Ni, Z. ;
Hu, Yu ;
Liang, W. ;
Ou, C. ;
He, J. ;
Liu, L. ;
Shan, H. ;
Lei, C. ;
Hui, D. S. C. ;
Du, B. ;
Li, L. ;
Zeng, G. ;
Yuen, K. -Y. ;
Chen, R. ;
Tang, C. ;
Wang, T. ;
Chen, P. ;
Xiang, J. ;
Li, S. ;
Wang, Jin-lin ;
Liang, Z. ;
Peng, Y. ;
Wei, L. ;
Liu, Y. ;
Hu, Ya-hua ;
Peng, P. ;
Wang, Jian-ming ;
Liu, J. ;
Chen, Z. ;
Li, G. ;
Zheng, Z. ;
Qiu, S. ;
Luo, J. ;
Ye, C. ;
Zhu, S. ;
Zhong, N. .
NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (18) :1708-1720
[3]   Advances in the understanding of the mechanism of action of IVIg [J].
Hartung, Hans-Peter .
JOURNAL OF NEUROLOGY, 2008, 255 (Suppl 3) :3-6
[4]   Hyperimmune IV Immunoglobulin Treatment A Multicenter Double-Blind Randomized Controlled Trial for Patients With Severe 2009 Influenza A(H1N1) Infection [J].
Hung, Ivan F. N. ;
To, Kelvin K. W. ;
Lee, Cheuk-Kwong ;
Lee, Kar-Lung ;
Yan, Wing-Wa ;
Chan, Kenny ;
Chan, Wai-Ming ;
Ngai, Chun-Wai ;
Law, Kin-Ip ;
Chow, Fu-Loi ;
Liu, Raymond ;
Lai, Kang-Yiu ;
Lau, Candy C. Y. ;
Liu, Shao-Haei ;
Chan, Kwok-Hung ;
Lin, Che-Kit ;
Yuen, Kwok-Yung .
CHEST, 2013, 144 (02) :464-473
[5]   Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges [J].
Lai, Chih-Cheng ;
Shih, Tzu-Ping ;
Ko, Wen-Chien ;
Tang, Hung-Jen ;
Hsueh, Po-Ren .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2020, 55 (03)
[6]   Immunoglobulins in the treatment of COVID-19 infection: Proceed with caution! [J].
Nguyen, Alan A. ;
Habiballah, Saddiq B. ;
Platt, Craig D. ;
Geha, Raif S. ;
Chou, Janet S. ;
McDonald, Douglas R. .
CLINICAL IMMUNOLOGY, 2020, 216
[7]   Estimates of the severity of coronavirus disease 2019: a model-based analysis [J].
Verity, Robert ;
Okell, Lucy C. ;
Dorigatti, Ilaria ;
Winskill, Peter ;
Whittaker, Charles ;
Imai, Natsuko ;
Cuomo-Dannenburg, Gina ;
Thompson, Hayley ;
Walker, Patrick G. T. ;
Fu, Han ;
Dighe, Amy ;
Griffin, Jamie T. ;
Baguelin, Marc ;
Bhatia, Sangeeta ;
Boonyasiri, Adhiratha ;
Cori, Anne ;
Cucunuba, Zulma ;
FitzJohn, Rich ;
Gaythorpe, Katy ;
Green, Will ;
Hamlet, Arran ;
Hinsley, Wes ;
Laydon, Daniel ;
Nedjati-Gilani, Gemma ;
Riley, Steven ;
van Elsland, Sabine ;
Volz, Erik ;
Wang, Haowei ;
Wang, Yuanrong ;
Xi, Xiaoyue ;
Donnelly, Christl A. ;
Ghani, Azra C. ;
Ferguson, Neil M. .
LANCET INFECTIOUS DISEASES, 2020, 20 (06) :669-677
[8]   Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China [J].
Wang, Dawei ;
Hu, Bo ;
Hu, Chang ;
Zhu, Fangfang ;
Liu, Xing ;
Zhang, Jing ;
Wang, Binbin ;
Xiang, Hui ;
Cheng, Zhenshun ;
Xiong, Yong ;
Zhao, Yan ;
Li, Yirong ;
Wang, Xinghuan ;
Peng, Zhiyong .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2020, 323 (11) :1061-1069
[9]   Contrasting Mechanisms of Interferon-α Inhibition by Intravenous Immunoglobulin After Induction by Immune Complexes Versus Toll-like Receptor Agonists [J].
Wiedeman, Alice E. ;
Santer, Deanna M. ;
Yan, Wei ;
Miescher, Sylvia ;
Kaesermann, Fabian ;
Elkon, Keith B. .
ARTHRITIS AND RHEUMATISM, 2013, 65 (10) :2713-2723
[10]   An Update on Current Therapeutic Drugs Treating COVID-19 [J].
Wu R. ;
Wang L. ;
Kuo H.-C.D. ;
Shannar A. ;
Peter R. ;
Chou P.J. ;
Li S. ;
Hudlikar R. ;
Liu X. ;
Liu Z. ;
Poiani G.J. ;
Amorosa L. ;
Brunetti L. ;
Kong A.-N. .
Current Pharmacology Reports, 2020, 6 (3) :56-70